Fredun Pharmaceuticals Limited has recently disclosed a comprehensive list of Ultimate Beneficial Owners (UBOs) for the proposed allottees in connection with the preferential allotment of equity shares and warrants. This disclosure follows the Extra-Ordinary General Meeting (EGM) held on October 22, 2025, and aims to ensure complete transparency and regulatory compliance in the preferential allotment process.

Key Details of the Disclosure

The company has provided details for 17 proposed allottees, including their respective UBO information. This disclosure supersedes earlier communications and provides a clear picture of the ownership structure behind the allotment. Some of the notable allottees and their UBOs include:

1. Alchemy Capital Management Pvt Ltd

   • Lashit Lallubhai Sanghvi
   • Ashwin Kedia
   • Mrs. Rekha Jhunjhunwala (Principal executor on behalf of "Estate of Late Shri. Rakesh Jhunjhunwala")

2. R R Family Trust

   • Mr. Ramesh Thakurdas Jaisinghani
   • Ms. Reina Ramesh Jaisinghani

3. Priyabhakta Commotrade Private Limited

   • Mr. Akhilesh Saraogi
   • Ms. Shruti Saraogi

Transparency and Compliance

This detailed disclosure aligns with Fredun Pharmaceuticals' commitment to transparency and adherence to regulatory requirements. By providing this information, the company ensures that all stakeholders have a clear understanding of the ownership structure behind the preferential allotment.

Recent Financial Performance

While not directly related to the UBO disclosure, it's worth noting that Fredun Pharmaceuticals has recently reported financial results for Q2 and H1 FY'26:

Q2 FY'26 Results

EBITDA margin improved to 15.37%.

H1 FY'26 Results

These results demonstrate the company's performance and growth trajectory, which may be of interest to potential investors involved in the preferential allotment.

Conclusion

Fredun Pharmaceuticals' disclosure of the UBO list for the preferential allotment demonstrates the company's commitment to transparency and regulatory compliance. This move provides clarity to all stakeholders and reinforces the company's dedication to maintaining high standards of corporate governance.

Fredun Pharmaceuticals Limited , a prominent player in the pharmaceutical sector, has announced a significant change in its corporate structure. Parag Goyal, who has been serving as the Company Secretary and Compliance Officer, is set to resign from his position.

Key Details of the Resignation

• Effective Date: Parag Goyal's resignation will take effect from the close of working hours on November 26, 2025.
• Reason: The resignation has been attributed to personal commitments.
• Acceptance: The Board of Directors has accepted Goyal's resignation.

Company's Response

Fredun Pharmaceuticals has stated that it will inform the stock exchanges once a new Company Secretary and Compliance Officer is appointed. This move ensures transparency and compliance with regulatory requirements.

Acknowledgment

In his resignation letter, Parag Goyal expressed gratitude for the opportunity to serve Fredun Pharmaceuticals Limited. He acknowledged the trust, support, and cooperation extended to him by all members of the Board during his tenure.

Regulatory Compliance

The company has duly informed the BSE Ltd. about this development, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Fredun Pharmaceuticals has also provided the necessary details as required under these regulations.

Financial Performance Context

While this corporate change is taking place, it's worth noting that Fredun Pharmaceuticals has recently reported its financial results for the quarter and half-year ended September 30, 2025. The Board of Directors approved these unaudited financial results in a meeting held on November 8, 2025.

This corporate governance update comes at a time when the company has shown strong financial performance, with a significant increase in net sales and profitability compared to the previous year.

As Fredun Pharmaceuticals navigates this transition in its key compliance role, stakeholders will be watching for the appointment of a new Company Secretary and Compliance Officer to ensure continued adherence to regulatory standards and smooth corporate operations.